Preclinical studies showed that, similar to ABT-737, venetoclax is particularly active against MM cell lines and patient samples with a t(11;14) translocation and high BCL2/MCL1 mRNA ratios [79]. Here, MCL1 is linked to Miyoshi myopathy.